Genelux (GNLX) Long-Term Debt Repayments (2022 - 2023)

Genelux (GNLX) recorded quarterly Long-Term Debt Repayments of $25000.0 in Q3 2023, down 87.5% quarter-over-quarter from $200000.0 in Q2 2023.

Genelux (GNLX) Long-Term Debt Repayments (2022 - 2023) Analysis & Trends

Genelux's Long-Term Debt Repayments history runs 2 years deep, the most recent figure standing at $25000.0 for Q3 2023.

In Q3 2023, Long-Term Debt Repayments changed N/A year-over-year to $25000.0; the TTM figure through Dec 2023 stood at $685000.0 (changed N/A YoY), while the FY2023 annual figure was $685000.0, up 426.92% from the prior year.
Long-Term Debt Repayments was $25000.0 for Q3 2023 at Genelux, down from $200000.0 in the prior quarter.
In the past five years, Long-Term Debt Repayments ranged from a high of $460000.0 in Q1 2023 to a low of $25000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-21,671.00
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Genelux	129.36 Mn	129.36 Mn	-	-

Download Data